Coronavirus Notebook: WHO Backs Actemra & Kevzara In COVID-19, German Body Says Remdesivir Has ‘Considerable Added Benefit’
The UK REACT-1 study has shown a threefold reduction in COVID-19 infections in double-vaccinated adults.
You may also be interested in...
Three authorized products currently used for arthritis and other conditions have now been filed for approval in Europe for treating people with severe COVID-19.
The World Health Organization has taken the unusual step of calling for lower drug prices to help COVID-19 patients access IL-6 therapies in developing nations.
The latest initiative under the UK’s Life Sciences Vision is intended to fund the development of innovative treatments while saving the National Health Service “millions of pounds.”